Startups
Edit
Neuralstem, Inc.
http://www.neuralstem.com/Last activity: 17.09.2018
Active - Reference to Palisade Bio
Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia.
Overview
Employees
11-50
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 10, 2017 | Celgene's Michael Pehl leaps up to lead role at Immunomedics; GSK nabs Hal Barron to helm R&D; Aimmune CEO to step down | Michael Pehl → Michael Pehl will take the top job at Immunomedics next month after 11 years at Celgene, where he was most recently head of hematology and oncology. As president and CEO, his priority will be pushing for the a... |
| Dec 12, 2016 | Neuralstem Closes $20M Investment | GERMANTOWN, Md., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announces the closing of ... |
| Mar 14, 2014 | New Mexico startup looks to bring to market a drug to stop brain injury during stroke | Between 80 and 90 percent of strokes are caused by blood clots that interrupt blood flow to the brain. tPA, the only FDA-approved drug for stroke, dissolves that clot and restores blood flow to the brain. But it’s used cautiously by medical... |
| Apr 17, 2013 | CoFoundersLab hits 10K members in online, ‘team-building’ platform [Startup Roundup] | This is the Startup Roundup. Every Wednesday morning, Technically Baltimore will put together the smaller pieces that make up our startup ecosystem. If you’ve got news to share, get in touch.who’s getting funded? Ankota, based in Canton, ha... |
| Aug 27, 2010 | Neuralstem aims to treat paralysis in spinal injury stem cell trial | Neuralstem Inc. (AMEX:CUR) asked the Food & Drug Administration for permission to begin a clinical trial of a chronic spinal injury treatment using stem cells. The Rockville, Md.-based company’s Phase I clinical safety trial would emplo... |
| New Mexico startup looks to bring to market a drug to stop brain injury during stroke | One of the most challenging things about the gold standard for stroke treatment, the drug tPA, is that to most effectively prevent long-term brain damage, it has to be given within three hours of stroke onset. A New Mexico drug startup call... |
Reviews 0
FAQ about Neuralstem, Inc.
What has the press written about Neuralstem, Inc.?
Parsers VC has collected 7 articles mentioning Neuralstem, Inc., among them “Celgene's Michael Pehl leaps up to lead role at Immunomedics; GSK nabs Hal Barron to helm R&D; Aimmune CEO to step down” (Nov 10, 2017) and “Neuralstem Closes $20M Investment” (Dec 12, 2016).
Is Neuralstem, Inc. still active?
Yes, Neuralstem, Inc. is active; its latest activity on Parsers VC dates from Sep 17, 2018.